<DOC>
	<DOCNO>NCT00003002</DOCNO>
	<brief_summary>RATIONALE : Vaccines make HER2/neu antigen may make body build immune response kill tumor cell . Colony-stimulating factor GM-CSF increase number immune cell find bone marrow peripheral blood . PURPOSE : Phase I trial study effectiveness HER-2/neu vaccine plus GM-CSF treating patient stage III stage IV breast cancer , stage III stage IV ovarian cancer , stage III stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>HER-2/Neu Vaccine Plus GM-CSF Treating Patients With Stage III Stage IV Breast , Ovarian , Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety serial intradermal vaccination HER-2/neu derive peptide sargramostim ( GM-CSF ) adjuvant patient stage III IV HER-2/neu express breast , ovarian , nonsmall cell lung cancer . II . Determine whether immunity elicit peptide derive intracellular domain HER-2/neu protein . III . Determine whether immunity elicit peptide derive extracellular domain HER-2/neu protein . IV . Determine whether cytotoxic T cell specific HER-2/neu protein elicit patient HLA-A2 immunization peptide derive HER-2/neu protein . OUTLINE : Patients receive one three HER-2/neu peptide vaccine formulation also contain sargramostim ( GM-CSF ) vaccine adjuvant . Each vaccine study 20 patient . A maximum 3 patient receive vaccine month 6 month monitor potential toxicity associate sequential immunization . Patients receive follow-up evaluation 1 month last vaccination . Those patient immune response relate vaccine continue immunologic evaluation perform every 2 month immune response still detect . PROJECTED ACCRUAL : 60 patient accrue .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage III IV breast , ovarian , nonsmall cell lung cancer ( NSCLC ) : Adenocarcinoma No progressive disease May comlpeted least 1 standard chemotherapy regimen Confirmed HER2/neu protein overexpression tumor ( either primary tumor metastasis ) PATIENT CHARACTERISTICS : Age : Pre postmenopausal Performance status : Not specify Life expectancy : At least 12 month Hematopoietic : WBC great 3,500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 1.5 mg/dL Renal : Creatinine le 1.5 mg/dL Creatinine clearance great 60 mL/min Other : No anergy ( positive delay type hypersensitivity response require two common recall antigen ) Female patient must nonfertile Male patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 1 month since cytotoxic chemotherapy Endocrine therapy : At least 1 month since corticosteroid therapy Concurrent hormone therapy allow Radiotherapy : Concurrent radiation therapy local control disease allow ( except initial therapy NSCLC ) Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>stage III breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage III non-small cell lung cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
</DOC>